Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 4
2015 1
2016 1
2017 8
2018 12
2019 11
2020 25
2021 21
2022 26
2023 38
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Inclisiran: First Approval.
Lamb YN. Lamb YN. Drugs. 2021 Feb;81(3):389-395. doi: 10.1007/s40265-021-01473-6. Drugs. 2021. PMID: 33620677 Free PMC article. Review.
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Ray KK, et al. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187462 Clinical Trial.
PCSK9 Biology and Its Role in Atherothrombosis.
Barale C, Melchionda E, Morotti A, Russo I. Barale C, et al. Int J Mol Sci. 2021 May 30;22(11):5880. doi: 10.3390/ijms22115880. Int J Mol Sci. 2021. PMID: 34070931 Free PMC article. Review.
Inclisiran: A Review in Hypercholesterolemia.
Frampton JE. Frampton JE. Am J Cardiovasc Drugs. 2023 Mar;23(2):219-230. doi: 10.1007/s40256-023-00568-7. Epub 2023 Mar 4. Am J Cardiovasc Drugs. 2023. PMID: 36869996 Review.
The growth of siRNA-based therapeutics: Updated clinical studies.
Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. Zhang MM, et al. Biochem Pharmacol. 2021 Jul;189:114432. doi: 10.1016/j.bcp.2021.114432. Epub 2021 Jan 26. Biochem Pharmacol. 2021. PMID: 33513339 Free PMC article. Review.
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS; ORION Phase III investigators. Ray KK, et al. Eur Heart J. 2023 Jan 7;44(2):129-138. doi: 10.1093/eurheartj/ehac594. Eur Heart J. 2023. PMID: 36331326 Free PMC article.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Raal FJ, et al. N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32197277 Clinical Trial.
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, Talloczy Z, Zang X, Maheux P, Lesogor A, Landmesser U. Ray KK, et al. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. doi: 10.1016/S2213-8587(22)00353-9. Epub 2023 Jan 5. Lancet Diabetes Endocrinol. 2023. PMID: 36620965 Free article. Clinical Trial.
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A. Fitzgerald K, et al. Lancet. 2014 Jan 4;383(9911):60-68. doi: 10.1016/S0140-6736(13)61914-5. Epub 2013 Oct 3. Lancet. 2014. PMID: 24094767 Free PMC article. Clinical Trial.
The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. ...The proportions of patients affected by treatment-emer …
The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of …
145 results